Sarepta Theraps Inc Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for SAREPTA THERAPS INC, and what generic alternatives to SAREPTA THERAPS INC drugs are available?
SAREPTA THERAPS INC has three approved drugs.
There are twenty-three US patents protecting SAREPTA THERAPS INC drugs.
There are one hundred and fifty-five patent family members on SAREPTA THERAPS INC drugs in twenty-six countries.
Summary for Sarepta Theraps Inc
International Patents: | 155 |
US Patents: | 23 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 3 |
Drugs and US Patents for Sarepta Theraps Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 9,243,245 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Sarepta Theraps Inc | VYONDYS 53 | golodirsen | SOLUTION;INTRAVENOUS | 211970-001 | Dec 12, 2019 | RX | Yes | Yes | 10,968,450 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | RX | Yes | Yes | 9,243,245 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | 9,228,187 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Sarepta Theraps Inc | VYONDYS 53 | golodirsen | SOLUTION;INTRAVENOUS | 211970-001 | Dec 12, 2019 | RX | Yes | Yes | 10,421,966 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Sarepta Theraps Inc | VYONDYS 53 | golodirsen | SOLUTION;INTRAVENOUS | 211970-001 | Dec 12, 2019 | RX | Yes | Yes | 9,994,851 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | RE48468 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sarepta Theraps Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | 10,533,174 | ⤷ Try a Trial |
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | 10,533,174 | ⤷ Try a Trial |
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | 10,533,174 | ⤷ Try a Trial |
Sarepta Theraps Inc | VYONDYS 53 | golodirsen | SOLUTION;INTRAVENOUS | 211970-001 | Dec 12, 2019 | 9,416,361 | ⤷ Try a Trial |
Sarepta Theraps Inc | VYONDYS 53 | golodirsen | SOLUTION;INTRAVENOUS | 211970-001 | Dec 12, 2019 | 10,533,174 | ⤷ Try a Trial |
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | 9,416,361 | ⤷ Try a Trial |
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | 9,416,361 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Sarepta Theraps Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 5905260 | ⤷ Try a Trial |
Japan | 2013510561 | ⤷ Try a Trial |
Canada | 2741629 | ⤷ Try a Trial |
China | 101896186 | ⤷ Try a Trial |
Canada | 2741793 | ⤷ Try a Trial |
South Korea | 102239374 | ⤷ Try a Trial |
South Korea | 102000762 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.